Array Biopharma Phase 3 MILO study evaluating binimetinib in ovarian cancer enrolling globally

Array BioPharma Inc. continues recruitment for its ongoing Phase 3 clinical study in patients with low-grade serous ovarian cancer (LGSOC). The multinational, randomized Phase 3 study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the effectiveness of the investigational MEK inhibitor, binimetinib (MEK162), in comparison to that of selected chemotherapies. The primary endpoint is progression-free survival and the key secondary endpoint is overall survival.

Initiated in June 2013, the MILO study is enrolling patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum. In the study, patients will receive either investigational study drug binimetinib or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan).

To learn more about the MILO study, patients and physicians can visit the study's website www.themilostudy.com or Clinicaltrials.gov.